Neoplastic Process
Thousands Could Benefit from New Take-at-Home Treatment for Advanced Prostate Cancer
prostate cancer; talazoparib; Talzenna; NICE; NHS; enzalutamide
J&J Targets $100 Billion in 2026 Sales Despite Stelara Patent Cliff
Johnson & Johnson; J&J; 2026 sales; $100 billion; Stelara; patent cliff; DARZALEX; oncology; MedTech; Shockwave Medical
FDA Issues Draft Guidance on MRD and CR Endpoints for Accelerated Multiple Myeloma Drug Approvals
FDA guidance; multiple myeloma; MRD; complete response; accelerated approval
BMS and Microsoft Partner to Advance AI-Driven Lung Cancer Detection
Bristol Myers Squibb; Microsoft; lung cancer; AI workflows; Precision Imaging Network; NSCLC
Moderna and Merck Report Sustained 49% Risk Reduction in Recurrence or Death with mRNA-Keytruda Combo at Five Years in Melanoma Trial
Moderna; Merck; Keytruda; intisemeran autogene; mRNA-4157; melanoma; recurrence-free survival; Phase 2b
AstraZeneca Acquires Complete Global Rights to AbelZeta’s C-CAR031 CAR-T Therapy for Up to $630 Million
AstraZeneca; AbelZeta; C-CAR031; CAR-T; GPC3; China rights; $630M; hepatocellular carcinoma; HCC
Genmab and AbbVie’s Epcoritamab Misses Overall Survival Endpoint but Meets PFS in Phase 3 DLBCL Trial
Genmab; AbbVie; epcoritamab; Epkinly; EPCORE DLBCL-1; Phase 3; DLBCL; lymphoma; overall survival; progression-free survival
J&J Reports Positive Phase 3 MajesTEC-9 Results for Tecvayli in Earlier Multiple Myeloma
Tecvayli; J&J; Phase 3; MajesTEC-9; multiple myeloma; PFS; OS
Bristol Myers Squibb Completes $4.8 Billion Acquisition of Mirati Therapeutics
Bristol Myers Squibb; Mirati Therapeutics; acquisition; $4.8 billion; KRAZATI; oncology; KRAS G12C
FDA Lifts Partial Hold on Merck and Daiichi Sankyo’s B7-H3 ADC Trial for Lung Cancer[6]
FDA; partial hold lifted; Merck; Daiichi Sankyo; ifinatamab deruxtecan; I-DXd; B7-H3 ADC; small cell lung cancer; IDeate-Lung02